PC
NKGN icon

Periscope Capital’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Periscope Capital’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-25,000
Closed -$16.4K – 236
2024
Q4 		$16.4K Buy
+25,000
New +$10.2K 0.01% 144
2023
Q4 		– Sell
-347,994
Closed -$3.61M – 513
2023
Q3 		$3.61M Hold
347,994
– – 0.41% 88
2023
Q2 		$3.59M Sell
347,994
-865,552
-71% -$8.86M 0.28% 126
2023
Q1 		$12.3M Buy
1,213,546
+456,046
+60% +$4.6M 0.57% 48
2022
Q4 		$7.54M Buy
757,500
+158,700
+27% +$1.57M 0.32% 99
2022
Q3 		$5.84M Sell
598,800
-400
-0.1% -$3.9K 0.17% 243
2022
Q2 		$5.82M Hold
599,200
– – 0.16% 263
2022
Q1 		$5.82M Hold
599,200
– – 0.15% 271
2021
Q4 		$5.8M Buy
+599,200
New +$5.83M 0.16% 264

Other funds holding NKGN

DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
UOC
University of Chicago Chicago, Illinois $420M AUM 42.14% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return

Periscope Capital's NKGN Position: Q1 2025 in Review

Periscope Capital sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q1 2025, closing a stake of 25,000 shares — an estimated $16.4K sold.

Periscope Capital first reported a position in NKGN in Q4 2021 and held it in 9 quarters. The position peaked at $12.3M in Q1 2023. 3 funds tracked by Wall St. Rank hold NKGN as of Q1 2025.

  • Periscope Capital reported no remaining NKGen Biotech, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Periscope Capital sold 25,000 NKGen Biotech, Inc. Common Stock shares in Q1 2025, an estimated $16.4K.
  • Periscope Capital first reported a position in NKGen Biotech, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
  • Periscope Capital's NKGen Biotech, Inc. Common Stock position peaked at $12.3M in Q1 2023.
  • 3 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q1 2025.

Based on Periscope Capital's 13F filing for Q1 2025, filed 13 May 2025.